



FOI REF: 23/351

28th June 2023

Tel: 0300 131 4500

Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

How many patients are currently registered with your Trust who are receiving or are set to receive high-tech homecare medicines and services?

- **Please provide this broken down by the treatment they are receiving or are set to receive.**

Please see attached document for the number of patients receiving high-tech treatment from East Sussex Healthcare NHS Trust's Community Health and Integrated Care Division (CHIC) and the Trust's Pharmacy Department.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net

FOI 23/351 - East Sussex Healthcare NHS Trust

**Community Health & Integrated Care Division
(CHIC)**

Care Plan	Active Number
Administration of Insulin	367
Administration of Stat Dose	1104
Administration of Syringe Drivers	2

Pharmacy Department

ReportGroup	Patient Count
Abatacept	17
Acalabrutinib	4
Adalimumab	62
Alirocumab	27
Apremilast	12
Atovaquone	1
Baricitinib	96
Bosutinib	6
Brodalumab	5
Certolizumab Pegol	25
Co-Trimoxazole	1
Dasatinib	1
Dupilumab	89
Erenumab	8
Etanercept	357
Evolocumab	59
Factor VIII Injection	1
Filgotinib	3
Filgrastim	1
Galcanezumab	73
Glatiramer	51
Golimumab	61
Guselkumab	11
Imatinib	1
Interferon Beta	31
Ixekizumab	9
Lanreotide	5
Lenalidomide	1
Methotrexate	257
Nilotinib	13
Omalizumab	8
Palbociclib	22
Romosozumab	3
Sarilumab	17
Secukinumab	135
Somatropin	4
Teriflunomide	36
Teriparatide	1
Tocilizumab	55
Tofacitinib	32
Tralokinumab	1
Trastuzumab	6
Ustekinumab	245
Vedolizumab	69